Drug Trial Radar · NCT04551248
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
Last checked: Nov 19, 2026Latest source record: Sep 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000,000
Planned (sponsor's estimate)
Start
Aug 1, 2021
Primary completion
Mar 31, 2022
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Sungkyunkwan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Government-wide R&D Fund project for infectious disease research
- First posted
- Sep 16, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this observational study is to examine the risk of adverse events following vaccination with 10 or 13-valent pneumococcal conjugate vaccine (PCV10 or PCV13) among infants or children age \<59 months and 23-valent pneumococcal polysaccharide vaccine (PPSV23) among adults age 65 years and older.
Conditions
- Pneumococcal Vaccine Adverse Reaction
Interventions
10 or 13-valent pneumococcal conjugate vaccineBiological
a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
23-valent pneumococcal polysaccharide vaccineBiological
Single 0.5-mL dose administered intramuscularly or subcutaneously only.
Influenza vaccineBiological
One dose of trivalent influenza vaccine in flu seasons.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative risk of adverse eventsTime frame: 2014-2018
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sungkyunkwan University
Suwon, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.